Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-06-14
2011-06-14
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C424S133100, C435S007100
Reexamination Certificate
active
07960517
ABSTRACT:
The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.
REFERENCES:
patent: 4816397 (1989-03-01), Boss
patent: 4816567 (1989-03-01), Cabilly
patent: 5225539 (1993-07-01), Winter
patent: 5530101 (1996-06-01), Queen
patent: 5585089 (1996-12-01), Queen
patent: 5639641 (1997-06-01), Pedersen
patent: 5693761 (1997-12-01), Queen
patent: 5693762 (1997-12-01), Queen
patent: 6180370 (2001-01-01), Queen
patent: 6329551 (2001-12-01), Nakagome
patent: 6331415 (2001-12-01), Cabilly
patent: 6342587 (2002-01-01), Barbas
patent: 2003/0198638 (2003-10-01), Watkins
patent: 2004/0086979 (2004-05-01), Zhang et al.
patent: 2005/0033031 (2005-02-01), Couto
Becker et al., Somatic Diversification of Immunoglobulin Heavy Chain VDJ Genes: Evidence for Somatic Gene Conversion in Rabbits, Cell, 63:987-997, (1990).
De Pascalis et al., Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody, J Imm., 2002, 169:3076-3084.
Delagrave et al., Effects of Humanization by Variable Domain Resurfacing on the Antiviral Activity of a Single-Chain Antibody Against Respiratory Syncytial Virus, Prot. Eng., 12: 357-362, (1999).
Knight et al., Molecular Basis of the Allelic Inheritance of Rabbit Immunoglobulin VH Allotypes: Implications for the Generation of Antibody Diversity, Cell, 60: 963-970, (1990).
Mehr et al., Analysis of Mutational Lineage Trees From Sites of Primary and Secondary Ig Gene Diversification in Rabbits and Chickens, J Immunol., 172:4790-6, (2004).
Morea et al., Antibody Modeling: Implications for Engineering and Design, Methods, 20: 267-279, (2000).
Popkov et al., Rabbit Immune Repertoires As Sources for Therapeutic Monoclonal Antibodies: The Impact of Kappa Allotype-Correlated Variation in Cysteine Content on Antibody Libraries Selected by Phage Display, J Mol Biol, 325:325-35, (2003).
Rader et al,.The Rabbit Antibody Repertoire as a Novel Source for the Generation of Therapeutic Human Antibodies, J. Biol. Chem., 275(13):13668-13676, (2000).
Rader et al., A Phage Display Approach for Rapid Antibody Humanization: Designed Combinatorial V Gene Libraries, Proc. Natl. Acad. Sci., 95:8910-8915, (1998).
Roguska et al., A Comparison of Two Murine Monoclonal Antibodies Humanized by CDR-Grafting and Variable Domain Resurfacing, Prot. Eng., 9: 895-904, (1996).
Roguska et al., Humanization of Murine Monoclonal Antibodies Through Variable Domain Resurfacing, Proc. Natl. Acad. Sci., 91: 969-973, (1994).
Steinberger et al., Generation and Characterization of a Recombinant Human CCR5-Specific Antibody, J. Bio. Chem., 275: 36073-36078, (2000).
Vaswani et al., Humanized Antibodies As Potential Therapeutic Drugs, Ann. Allergy Asthma Immunol., 81:105-119, (1998).
Couto Fernando Jose Rebelo Do
Hendricks Kristin B.
Wallace S. Ellen
Yu Guo-Liang
Bozicevic Field & Francis LLP
Epotimics, Inc.
Gussow Anne M.
Keddie James S.
LandOfFree
Methods for antibody engineering does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for antibody engineering, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for antibody engineering will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2743919